• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor.

作者信息

Uchida Naoya, Leonard Alexis, Stroncek David, Panch Sandhya R, West Kamille, Molloy Eoghan, Hughes Thomas E, Hauffe Sara, Taylor Tiffani, Fitzhugh Courtney, Hankins Jane S, Wilson Megan, Sharma Akshay, Tsai Shengdar Q, Weiss Mitch J, Hsieh Matthew, Tisdale John F

机构信息

NHLBI, NIDDK, National Institutes of Health (NIH), Bethesda, USA.

Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, USA.

出版信息

Haematologica. 2020 Oct 1;105(10):e497. doi: 10.3324/haematol.2019.236182.

DOI:10.3324/haematol.2019.236182
PMID:33054091
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7556661/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c5/7556661/14e0a2dd5253/105e497.fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c5/7556661/16f422c05d22/105e497.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c5/7556661/ef4f556c5840/105e497.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c5/7556661/dbe1ceca059e/105e497.fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c5/7556661/cc18a21b6e0a/105e497.fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c5/7556661/14e0a2dd5253/105e497.fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c5/7556661/16f422c05d22/105e497.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c5/7556661/ef4f556c5840/105e497.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c5/7556661/dbe1ceca059e/105e497.fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c5/7556661/cc18a21b6e0a/105e497.fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c5/7556661/14e0a2dd5253/105e497.fig5.jpg

相似文献

1
Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor.使用普乐沙福在镰状细胞病患者中进行安全有效的外周血干细胞采集。
Haematologica. 2020 Oct 1;105(10):e497. doi: 10.3324/haematol.2019.236182.
2
Successful Mobilization of Autologous Hematopoietic Peripheral Blood Stem Cells after Salvage Chemotherapy in Patients with Low CD34 Blood Cell Counts.低 CD34 血细胞计数患者挽救性化疗后自体造血外周血干细胞的成功动员。
Transplant Cell Ther. 2022 Nov;28(11):754-759. doi: 10.1016/j.jtct.2022.08.017. Epub 2022 Aug 22.
3
[The Influence of COVID-19 Infection on the Mobilization and Collection of Autologous Peripheral Blood Stem Cells in Patients with Multiple Myeloma].[新型冠状病毒肺炎感染对多发性骨髓瘤患者自体外周血干细胞动员及采集的影响]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2025 Apr;33(2):455-462. doi: 10.19746/j.cnki.issn.1009-2137.2025.02.021.
4
Development of a quantitative prediction model for peripheral blood stem cell collection yield in the plerixafor era.在培瑞克昔福 era 开发外周血造血干细胞采集产量的定量预测模型。
Cytotherapy. 2022 Jan;24(1):49-58. doi: 10.1016/j.jcyt.2021.09.004. Epub 2021 Oct 12.
5
Long-term safety of the stem cell releasing compound plerixafor for peripheral stem cell collection in myeloma patients.干细胞释放化合物普乐沙福用于骨髓瘤患者外周血干细胞采集的长期安全性。
Hematol Oncol. 2023 Aug;41(3):583-586. doi: 10.1002/hon.3055. Epub 2022 Aug 6.
6
Autologous peripheral blood stem cell mobilization and collection in patients with lymphoma and multiple myeloma: A single-center experience using the plerixa for pre-emptive approach.淋巴瘤和多发性骨髓瘤患者的自体外周血干细胞动员和采集：采用普乐沙福进行抢先治疗的单中心经验。
Saudi Med J. 2022 Jun;43(6):626-632. doi: 10.15537/smj.2022.43.6.20210912.
7
Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.普乐沙福用于既往接受氟达拉滨或来那度胺治疗的患者的自体外周血造血干细胞动员。
Biol Blood Marrow Transplant. 2012 Feb;18(2):314-7. doi: 10.1016/j.bbmt.2011.10.003. Epub 2011 Oct 13.
8
Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma.在恶性淋巴瘤或多发性骨髓瘤患者中，在使用粒细胞集落刺激因子的基础上加用普乐沙福用于造血干细胞动员以进行自体移植。
Cochrane Database Syst Rev. 2015 Oct 20;2015(10):CD010615. doi: 10.1002/14651858.CD010615.pub2.
9
Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.培洛昔福联合粒细胞集落刺激因子与安慰剂联合粒细胞集落刺激因子动员多发性骨髓瘤且外周血 CD34+细胞计数低的患者中的 CD34+造血干细胞：一项随机试验的亚组分析结果。
Biol Blood Marrow Transplant. 2012 Oct;18(10):1564-72. doi: 10.1016/j.bbmt.2012.05.017. Epub 2012 Jun 6.
10
[A Single-Center Analysis of the Use of G-CSF Combined with Plerixafor to Mobilize Peripheral Blood Hematopoietic Stem Cell from Healthy Related Donors in Allogeneic Hematopoietic Stem Cell Transplantation].[一项关于在异基因造血干细胞移植中使用粒细胞集落刺激因子（G-CSF）联合普乐沙福动员健康相关供者外周血造血干细胞的单中心分析]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022 Feb;30(1):286-291. doi: 10.19746/j.cnki.issn.1009-2137.2022.01.047.

引用本文的文献

1
To pursue gene therapy or not? Is it feasible after graft failure in allogeneic hematopoietic cell transplant recipients.是否进行基因治疗？对于异基因造血细胞移植受者移植失败后是否可行？
Blood Adv. 2025 Aug 12;9(15):3845-3852. doi: 10.1182/bloodadvances.2024015413.
2
Current and future treatments for sickle cell disease: From hematopoietic stem cell transplantation to in vivo gene therapy.镰状细胞病的当前及未来治疗方法：从造血干细胞移植到体内基因治疗。
Mol Ther. 2025 May 7;33(5):2172-2191. doi: 10.1016/j.ymthe.2025.03.016. Epub 2025 Mar 12.
3
Beyond the traditional oncology patient: the role of palliative care in patients with sickle cell disease receiving stem cell transplantation or gene therapy.
超越传统肿瘤患者：姑息治疗在接受干细胞移植或基因治疗的镰状细胞病患者中的作用。
Front Oncol. 2025 Feb 13;15:1535851. doi: 10.3389/fonc.2025.1535851. eCollection 2025.
4
Cooperative participation of CagA and NFATc1 in the pathogenesis of antibiotics-responsive gastric MALT lymphoma.CagA与NFATc1在抗生素反应性胃黏膜相关淋巴组织淋巴瘤发病机制中的协同参与作用。
Cancer Cell Int. 2024 Nov 18;24(1):383. doi: 10.1186/s12935-024-03552-6.
5
How I treat sickle cell disease with gene therapy.我如何用基因疗法治疗镰状细胞病。
Blood. 2024 Dec 26;144(26):2693-2705. doi: 10.1182/blood.2024024519.
6
Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34 cell therapy to induce fetal hemoglobin for sickle cell disease.新型 Cas9 基因编辑自体 CD34 细胞疗法诱导镰状细胞病胎儿血红蛋白的开发和 IND 支持研究。
Mol Ther. 2024 Oct 2;32(10):3433-3452. doi: 10.1016/j.ymthe.2024.07.022. Epub 2024 Jul 31.
7
Hematopoietic stem cell collection for sickle cell disease gene therapy.镰状细胞病基因治疗的造血干细胞采集
Curr Opin Hematol. 2024 May 1;31(3):104-114. doi: 10.1097/MOH.0000000000000807. Epub 2024 Feb 9.
8
Effect of voxelotor on murine bone marrow and peripheral blood with hematopoietic progenitor cell mobilization for gene therapy of sickle cell disease.羟基脲对镰状细胞病基因治疗中用于造血祖细胞动员的小鼠骨髓和外周血的影响。
Blood Cells Mol Dis. 2024 Mar;105:102824. doi: 10.1016/j.bcmd.2024.102824. Epub 2024 Jan 19.
9
Gene therapy for sickle cell disease.镰状细胞病的基因治疗。
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):542-547. doi: 10.1182/hematology.2023000487.
10
CRISPR-Cas9 Editing of the and Promoters to Treat Sickle Cell Disease.CRISPR-Cas9 编辑 和 启动子以治疗镰状细胞病。
N Engl J Med. 2023 Aug 31;389(9):820-832. doi: 10.1056/NEJMoa2215643.